Takashi Taga

List of Publications by Year
in descending order

136 papers	1,777 citations	430442 18 h-index	315357 38 g-index
142 all docs	142 docs citations	142 times ranked	2364 citing authors

#	Article	IF	Citations
1	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	0.6	383
2	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell, 2019, 36, 123-138.e10.	7.7	93
3	Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood, 2010, 116, 4631-4638.	0.6	77
4	Acute myeloid leukemia in children: Current status and future directions. Pediatrics International, 2016, 58, 71-80.	0.2	71
5	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	0.6	69
6	Wholeâ€exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 476-489.	1.2	60
7	Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in nonâ€Down syndrome. Genes Chromosomes and Cancer, 2017, 56, 394-404.	1.5	51
8	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Advances, 2019, 3, 3157-3169.	2.5	51
9	Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. International Journal of Hematology, 2013, 98, 578-588.	0.7	47
10	Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood, 2012, 120, 1810-1815.	0.6	46
11	High <scp>PRDM</scp>16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to <scp>FLT</scp>3â€<scp>ITD</scp>,<scp>KMT</scp>2Aâ€<scp>PTD</scp>, and <scp>NUP</scp>98â€<scp>NSD</scp>1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group <scp>AML</scp>â€05 trial. British Journal of Haematology, 2016, 172, 581-591.	1.2	41
12	Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki Disease. , 2000, 63, 160-161.		36
13	Continuous and highâ€dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Pediatric Blood and Cancer, 2011, 57, 36-40.	0.8	35
14	EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. Haematologica, 2014, 99, e225-e227.	1.7	35
15	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica, 2014, 99, 299-307.	1.7	34
16	Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan. Pediatric Blood and Cancer, 2016, 63, 248-254.	0.8	33
17	Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. International Journal of Hematology, 2014, 100, 171-179.	0.7	31
18	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1515-1522.	2.0	24

#	Article	IF	Citations
19	Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. International Journal of Hematology, 2018, 107, 586-595.	0.7	20
20	Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. British Journal of Haematology, 2020, 188, 528-539.	1.2	20
21	Outcome of Adolescent and Young Adults with Acute Myeloid Leukemia Treated with Pediatric Protocols: A Report from the 3 Japanese Cooperative Studies. Blood, 2014, 124, 374-374.	0.6	20
22	Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group. British Journal of Haematology, 2014, 167, 80-86.	1.2	19
23	Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. Blood Advances, 2018, 2, 2879-2889.	2.5	19
24	<scp>CSF</scp>3R and <scp>CALR</scp> mutations in paediatric myeloid disorders and the association of <scp>CSF</scp>3R mutations with translocations, including t(8; 21). British Journal of Haematology, 2015, 170, 391-397.	1.2	18
25	ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1â€RUNX1T1 and associated with a better prognosis. Genes Chromosomes and Cancer, 2017, 56, 382-393.	1.5	18
26	Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Childrenâ€™s Cancer Group Multi-Center Seamless Phase IIâ€“III Randomized Trial (JPLSG AML-12). Japanese Journal of Clinical Oncology, 2018, 48, 587-593.	0.6	18
27	Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. International Journal of Hematology, 2015, 102, 318-326.	0.7	17
28	EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase. Haematologica, 2020, 105, 2118-2129.	1.7	17
29	High eventâ€free survival rate with minimumâ€ddoseâ€anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group. British Journal of Haematology, 2016, 174, 437-443.	1.2	16
30	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. International Journal of Hematology, 2018, 107, 201-210.	0.7	15
31	RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis. Blood, 2018, 131, 2266-2270.	0.6	15
32	Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. Bone Marrow Transplantation, 2019, 54, 393-401.	1.3	15
33	Hematopoietic Cell Transplantation Rescues Inflammatory Bowel Disease and Dysbiosis of Gut Microbiota in XIAP Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3767-3780.	2.0	15
34	The Autocrine Loop of Epidermal Growth Factor Receptor-Epidermal Growth Factor/Transforming Growth Factor-Î± in Malignant Rhabdoid Tumor Cell Lines: Heterogeneity of Autocrine Mechanism in TTC549. Japanese Journal of Cancer Research, 2001, 92, 269-278.	1.7	13
35	Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia. Pediatrics International, 2018, 60, 41-46.	0.2	13
36	Nationwide survey of therapy-related leukemia in childhood in Japan. International Journal of Hematology, 2018, 108, 91-97.	0.7	12

#	Article	IF	Citations
37	Multiplex fusion gene testing in pediatric acute myeloid leukemia. Pediatrics International, 2018, 60, 47-51.	0.2	12
38	Retrospective analysis of children with highâ€risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AMLâ€05 clinical trial. Pediatric Blood and Cancer, 2019, 66, e27875.	0.8	12
39	Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML â€05 study. British Journal of Haematology, 2019, 185, 284-288.	1.2	12
40	CXCR4Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatric Blood and Cancer, 2016, 63, 1394-1399.	0.8	11
41	The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AMLâ€05R study. Pediatric Blood and Cancer, 2021, 68, e28736.	0.8	11
42	Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome. Leukemia, 2021, 35, 1480-1484.	3.3	11
43	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica, 2021, , .	1.7	10
44	Prospective Study of 168 Infants with Transient Abnormal Myelopoiesis with Down Syndrome: Japan Pediatric Leukemia/Lymphoma Study Group, TAM-10 Study. Blood, 2015, 126, 1311-1311.	0.6	10
45	Epsteinâ€“Barr virusâ€related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma. Journal of Medical Virology, 2011, 83, 1582-1584.	2.5	8
46	Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. International Journal of Hematology, 2018, 108, 306-311.	0.7	8
47	Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Genes Chromosomes and Cancer, 2020, 59, 160-167.	1.5	8
48	Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without coreâ€binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatric Blood and Cancer, 2020, 67, e28692.	0.8	8
49	Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse. Pediatric Blood and Cancer, 2016, 63, 701-705.	0.8	7
50	Fludarabine, cytarabine, granulocyte colonyâ€stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia. Pediatrics International, 2017, 59, 1046-1052.	0.2	7
51	Fusion partnerâ€“specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Advances, 2020, 4, 4623-4631.	2.5	7
52	Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia. Blood Advances, 2022, 6, 3207-3219.	2.5	7
53	Contribution of UGT1A1 variations to chemotherapy-induced unconjugated hyperbilirubinemia in pediatric leukemia patients. Pediatric Research, 2016, 80, 252-257.	1.1	6
54	Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan. International Journal of Hematology, 2018, 108, 438-442.	0.7	6

#	Article	IF	Citations
55	Identification of Germline Non-coding Deletions in XIAP Gene Causing XIAP Deficiency Reveals a Key Promoter Sequence. Journal of Clinical Immunology, 2022, 42, 559-571.	2.0	6
56	Neuronal Differentiation of Ewing's Sarcoma Induced by Cholera Toxin B and Bromodeoxyuridineâ€"Establishment of Ewing's Sarcoma Cell Line and Histochemical Studyâ€". Pediatrics International, 1991, 33, 428-433.	0.2	5
57	Pediatric primary leptomeningeal lymphoma treated without cranial radiotherapy. Pediatric Blood and Cancer, 2007, 48, 477-478.	0.8	5
58	Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group. International Journal of Hematology, 2015, 102, 697-701.	0.7	5
59	Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AMLâ€05R study. Pediatric Blood and Cancer, 2017, 64, e26491.	0.8	5
60	Registrationâ€directed phase 1/2 trial of irinotecan for pediatric solid tumors. Pediatrics International, 2019, 61, 453-458.	0.2	5
61	Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia, 2021, 35, 2508-2516.	3.3	5
62	Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Childrenâ€™s Cancer Group. International Journal of Hematology, 2022, 116, 131-138.	0.7	5
63	Restriction fragment length polymorphisms on the q24â€“q28 region of X chromosome among Japanese population. Japanese Journal of Human Genetics, 1989, 34, 123-128.	0.8	4
64	Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26411.	0.8	4
65	Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. Bone Marrow Transplantation, 2021, 56, 1859-1865.	1.3	4
66	Advanced Childhood Testicular Yolk SacÂTumor With Bone Metastasis: AÂCase Report. Urology, 2015, 85, 671-673.	0.5	3
67	Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey. EJHaem, 2020, 1, 86-93.	0.4	3
68	Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatric Blood and Cancer, 2020, 67, e28181.	0.8	3
69	Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AMLâ€05 study. British Journal of Haematology, 2021, 193, 176-180.	1.2	3
70	Characteristics of genetic alterations of peripheral Tâ€cell lymphoma in childhood including identification of novel fusion genes: the Japan Childrenâ€™s Cancer Group (JCCG). British Journal of Haematology, 2021, 194, 718-729.	1.2	3
71	High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 2583-2583.	0.6	3
72	Familial hemophagocytic lymphohistiocytosis syndrome due to lysinuric protein intolerance: a patient with a novel compound heterozygous pathogenic variant in SLC7A7. International Journal of Hematology, 2022, 116, 635-638.	0.7	3

#	Article	IF	Citations
73	Flowcytometric Analysis of DNA Pattern of Cells Derived from Xeroderma Pigmentosum Aâ€“ Hypersensitivity to Vincristine, Etoposide and Methotrexateâ€“. Pediatrics International, 1990, 32, 262-268.	0.2	2
74	Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities. Pediatric Blood and Cancer, 2019, 66, e27942.	0.8	2
75	Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1â€RUNX1T1 transcripts. British Journal of Haematology, 2021, 194, 414-422.	1.2	2
76	CSF3R Gene Mutations In Myeloid Malignancy Of Childhood. Blood, 2013, 122, 1352-1352.	0.6	2
77	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. Blood, 2010, 116, 762-762.	0.6	2
78	Using the inÂvitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis. British Journal of Haematology, 2021, , .	1.2	2
79	A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20). Japanese Journal of Clinical Oncology, 0, , .	0.6	2
80	Successful unrelated umbilical cord blood cell transplantation without conditioning for a neonate with severe combined immunodeficiency. Pediatric Transplantation, 2011, 15, E152-5.	0.5	1
81	Topoisomerase IIÎ² immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Childrenâ€™s Cancer Group. Brain Tumor Pathology, 2021, 38, 109-121.	1.1	1
82	Post-Induction Minimal Residual Disease Measured By Flow Cytometry and Deep Sequencing of Mutant GATA1 Are Both Significant Prognostic Factors for Children with Myeloid Leukemia and Down Syndrome: A Nationwide Prospective Study of the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood, 2019, 134, 3848-3848.	0.6	1
83	Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey. Blood, 2019, 134, 2958-2958.	0.6	1
84	Coexistence and Prognostic Significance of EVI1 Expression and Driver Mutations in KMT2A-Rearranged Acute Myeloid Leukemia. Blood, 2019, 134, 1409-1409.	0.6	1
85	Predictive Factors of the Development of Leukemia in Patients with Transient Abnormal Myelopoiesis and Down Syndrome: The Jccg Study JPLSG TAM-10. Blood, 2019, 134, 3833-3833.	0.6	1
86	Augmented Consolidation Therapy Based on Minimal Residual Disease (MRD) and Analysis of the Measurement of Sequential MRD in Childhood Acute Lymphoblastic Leukemia : Children's Cancer and Leukemia Study Group of JAPAN (CCLSG), Cclsg ALL 2004 Protocol Study. Blood, 2015, 126, 3724-3724.	0.6	1
87	Clinical and Biological Features of Pediatric Acute Myeloid Leukemia with Primary Induction Failure in the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Study. Blood, 2016, 128, 1610-1610.	0.6	1
88	Sepsis in a 4-Month-Old Boy Due to Carbapenem-Resistant Characterized by AmpC Î²-Lactamase with Porin Loss. International Journal of Applied & Basic Medical Research, 2018, 8, 263-265.	0.2	1
89	Restriction fragment length polymorphisms of X chromosome among Japanese population. Japanese Journal of Human Genetics, 1989, 34, 285-289.	0.8	0
90	Undifferentiated sarcoma arising at lower thoracic spine with neuroblastoma-like dumbbell-shaped radiographic appearance in a 1-year-old girl. Spine Journal, 2014, 14, 719-720.	0.6	0

#	Article	IF	Citations
91	Purpura fulminans in congenital protein C deficiency successfully treated with fresh frozen plasma and thrombomodulin. Journal of Dermatology, 2018, 45, e165-e166.	0.6	0
92	Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. British Journal of Haematology, 2021, 192, e7-e11.	1.2	0
93	Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19â€negative acute lymphoblastic leukemia after CARâ€T cell therapy. Pediatric Blood and Cancer, 2021, 68, e28980.	0.8	0
94	Low-Dose Cytosine Arabinoside Therapy for Neonates with Down Syndrome (DS) and Transient Leukemia (TL).. Blood, 2010, 116, 1074-1074.	0.6	0
95	Myeloid Leukemia of Down Syndrome: The Results of An International Retrospective Study. Blood, 2010, 116, 2718-2718.	0.6	0
96	A Rapid Approach for the Integrated Central Review of Acute Myeloid Leukemia Diagnosis In a Nationwide Clinical Trial for Children. Blood, 2010, 116, 4833-4833.	0.6	0
97	Heterogeneity in Infants with Acute Myeloid Leukemia: Retrospective Analysis of a Japanese Nationwide Survey. Blood, 2011, 118, 1477-1477.	0.6	0
98	Refractory / Relapsed Myeloid Leukemia of Down Syndrome Is Resistant to Second-Line Chemotherapy and Hardly Salvaged by Hematopoietic Stem Cell Transplantation: A Retrospective Study by the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG). Blood, 2011, 118, 4276-4276.	0.6	0
99	Multicenter phase I/II trial of topotecan (T) and ifosfamide (I) combination as second-line therapy for pediatric solid cancer: Phase II results.. Journal of Clinical Oncology, 2013, 31, 10050-10050.	0.8	0
100	Low Frequency and Poor Prognosis Of MLL-Partial Tandem Duplications In Pediatric Acute Myeloid Leukemia Using MLPA Method: The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Trial. Blood, 2013, 122, 1374-1374.	0.6	0
101	Double CEBPA Mutations Are Not Associated With Favorable Clinical Outcome In Pediatric AML: A Report From The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Blood, 2013, 122, 4942-4942.	0.6	0
102	Comprehensive Fusion Gene Analysis Of Pediatric Non-Down Syndrome Acute Megakaryoblasitc Leukemia. Blood, 2013, 122, 2646-2646.	0.6	0
103	Poor Prognosis With Different Induction Rate Was Observed In Children With Acute Myeloid Leukemia and FLT3-ITD According To The ITD/WT Allelic Ratio: A Result From The Japanese Pediatric Leukemia/Lymphoma Study Group. Blood, 2013, 122, 3891-3891.	0.6	0
104	A combination chemotherapy, temozolomide (TMZ) with etoposide (VP), in relapsed or refractory pediatric solid cancer: Preliminary report of randomized phase II study of two different outpatient setting regimens (rPII).. Journal of Clinical Oncology, 2014, 32, 10055-10055.	0.8	0
105	Clinical Features of Patients with ASXL1 and ASXL2 Mutations in Pediatric Acute Myeloid Leukemia. Blood, 2014, 124, 1024-1024.	0.6	0
106	The Prognostic Impact of High MEL1 Gene Expression in Pediatric Acute Myeloid Leukemia. Blood, 2014, 124, 1009-1009.	0.6	0
107	High Event-Free Survival Rate with Minimum-Dose-Anthracycline Treatment in Childhood Acute Promyelocytic Leukemia: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG). Blood, 2014, 124, 956-956.	0.6	0
108	Recombinant Thrombomodulin Safely Controls Disseminated Intravascular Coagulopathy in Acute Promyelocytic Leukemia â€“ Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-P05 Study. Blood, 2014, 124, 5097-5097.	0.6	0

#	Article	IF	Citations
109	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. Blood, 2014, 124, 481-481.	0.6	0
110	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG). Blood, 2014, 124, 3670-3670.	0.6	0
111	Poor Prognosis Associated with FAB Subtypes M4 and M5 in Japanese Pediatric Acute Myeloid Leukemia Patients with FLT3-ITD. Blood, 2014, 124, 1002-1002.	0.6	0
112	The Outcome of Relapsed Childhood Core Binding Factor Acute Myeloid Leukemia: A Report from the JPLSG AML-05R Study. Blood, 2015, 126, 2516-2516.	0.6	0
113	A Combination of EVI1 and PRDM16 Expression Clarified the Clinical Features of Intermediate/High Risk Patients in Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 1380-1380.	0.6	0
114	Prognostic Significance of CXCR4 Overexpression in Pediatric Acute Myeloid Leukemia with Low-Risk: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood, 2015, 126, 3814-3814.	0.6	0
115	Distinct Clinical and Cytogenetic Characteristics and Poor Prognosis in Children with Acute Erythroid Leukemia: A Report from the JPLSG AML-05 Study. Blood, 2015, 126, 4945-4945.	0.6	0
116	Detection of Novel Pathogenic Gene Rearrangements in Pediatric Acute Myeloid Leukemia By RNA Sequencing. Blood, 2015, 126, 2575-2575.	0.6	0
117	Final report of randomized phase II study of two different outpatient setting regimens, vinorelbine (VNR) with cyclophosphamide (CPA) and temozolomide (TMZ) with etoposide (VP).. Journal of Clinical Oncology, 2016, 34, 10550-10550.	0.8	0
118	Identification of Two Distinct Poor Prognostic Subgroups Related to High Expression of BMP2 or PRDM16 in Pediatric AML. Blood, 2016, 128, 2854-2854.	0.6	0
119	Transcriptome Analysis Revealed the Entire Genetic Understanding of Pediatric Acute Myeloid Leukemia with a Normal Karyotype. Blood, 2016, 128, 2850-2850.	0.6	0
120	Adolescents and Young Adults with Acute Myeloid Leukemia Are Associated with Higher Treatment-Related Mortality and Inferior Overall Survival after Allogeneic Hematopoietic Cell Transplantation Compared with Children. Blood, 2016, 128, 4702-4702.	0.6	0
121	Analysis of GATA1 Mutations in Down Syndrome Infants with Transient Abnormal Myelopoiesis and Clinical Impacts of GATA1 Mutation Types: A Report from the JPLSG TAM-10 Study. Blood, 2016, 128, 2865-2865.	0.6	0
122	Retrospective Evaluation of Correlations Between Genetic Backgrounds and Stem Cell Transplantation for De Novo Pediatric Acute Myeloid Leukemia: A Study from the Japan Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Clinical Trial. Blood, 2016, 128, 2904-2904.	0.6	0
123	Acute Myeloid Leukemia. , 2017, , 61-85.		0
124	Hematopoietic Stem-Cell Transplantation in Children with Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 4632-4632.	0.6	0
125	Comprehensive Analysis of 343 Genes Using Targeted Sequencing Panel By Next-Generation Sequencer in 77 Pediatric AML Patients with Normal and Complex Karyotypes: Jccg Study, JPLSG AML-05. Blood, 2018, 132, 1530-1530.	0.6	0
126	Recurrent Genomic Aberrations of D-Type Cyclins Are Therapeutic Targets of CDK4/6 Inhibitors in t(8;21) and MLL-Rearranged Acute Myeloid Leukemia. Blood, 2018, 132, 2797-2797.	0.6	0

#	Article	IF	Citations
127	Negative CD19 Expression Is Associated with Inferior Relapse-Free Survival in RUNX1-RUNX1T1-Positive Acute Myeloid Leukemia; The Japanese Pediatric Leukemia/Lymphoma Study Group Experience from the AML-05 Study. Blood, 2018, 132, 2810-2810.	0.6	0
128	Effect of Age on the Prognosis of Molecular Abnormalities in Pediatric Acute Myeloid Leukemia. Blood, 2018, 132, 1506-1506.	0.6	0
129	Significant Features of DNA Methylation at Bivalent Promotor and Repressed Polycomb Regions in Pediatric AML-the Jccg Study, JPLSG AML-05-. Blood, 2019, 134, 2739-2739.	0.6	0
130	Clinical Features of Pediatric Acute Myeloid Leukemia with TP53 and CDKN2A/2B copy Number Alterations. Blood, 2019, 134, 2727-2727.	0.6	0
131	Recurrent Gene Mutations in Pediatric Patients with AML By Targeted Sequencing â€•the Jccg Study, JPLSG AML-05â€•. Blood, 2019, 134, 2697-2697.	0.6	0
132	The Detection of Minor Clones with Somatic KIT D816V Mutations Using Droplet Digital PCR in Pediatric De Novo AML: AML-05 Trial from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood, 2019, 134, 1419-1419.	0.6	0
133	Clonal Evolution Pattern and Prognostic Significance of Clonal Architecture in KMT2A-Rearranged Acute Myeloid Leukemia. Blood, 2021, 138, 2358-2358.	0.6	0
134	Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity. Blood, 2020, 136, 14-15.	0.6	0
135	Etoposide, Cytarabine and Mitoxantrone- or Fludarabine, Cytarabine and Granulocyte Colony-Stimulating Factor-Based Intensive Reinduction Chemotherapy Is Recommended for Children with Relapsed Acute Myeloid Leukemia: The Results from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R Study. Blood, 2020, 136, 6-6.	0.6	0
136	KRAS mutations Frequently Coexist with High-Risk MLL Fusions and Are Independent Adverse Prognostic Factors in MLL-Rearranged Acute Myeloid Leukemia. Blood, 2020, 136, 28-29.	0.6	0